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ABSTRACT
SynergyFinder (https://synergyfinder.fimm.fi) is a
stand-alone web-application for interactive analy-
sis and visualization of drug combination screening
data. Since its first release in 2017, SynergyFinder
has become a widely used web-tool both for the
discovery of novel synergistic drug combinations in
pre-clinical model systems (e.g. cell lines or primary
patient-derived cells), and for better understanding
of mechanisms of combination treatment efficacy or
resistance. Here, we describe the latest version of
SynergyFinder (release 2.0), which has extensively
been upgraded through the addition of novel features
supporting especially higher-order combination data
analytics and exploratory visualization of multi-drug
synergy patterns, along with automated outlier de-
tection procedure, extended curve-fitting function-
ality and statistical analysis of replicate measure-
ments. A number of additional improvements were
also implemented based on the user requests, in-
cluding new visualization and export options, up-
dated user interface, as well as enhanced stability
and performance of the web-tool. With these im-
provements, SynergyFinder 2.0 is expected to greatly
extend its potential applications in various areas
of multi-drug combinatorial screening and precision
medicine.
INTRODUCTION
Drug combinations have become a standard therapy for
various complex diseases, including tuberculosis, malaria,
HIV, and most of the advanced cancers (1–5). This is be-
causemulti-targeted treatments can lead to therapeutic ben-
efits both by enhancing the treatment efficacy and by avoid-
ing the acquisition of monotherapy resistance (6). Further-
more, in some cases, combinatorial treatments can be ad-
ministered at lower doses of single drugs that would lead to
intolerable dose ranges if used as monotherapies (7), thus
reducing treatment side-effects. High-throughput combina-
torial screening is an established approach to identify new
synergistic drug combinations, i.e. combinations that result
in a higher than expected effects (8). The degree of com-
bination synergy, or antagonism, is quantified by compar-
ing the observed drug combination response against the ex-
pected response, calculated using a reference model that as-
sumes no interaction between drugs. The commonly-used
reference models include the highest single agent (HSA)
(9), Bliss (10), Loewe (11) and Zero interaction potency
(ZIP) model (12). Drug combinations showing the highest
synergy among all the combinations screened are then se-
lected for further development and testing toward safe and
effective treatment options. Hence, easy-to-use tools that
enable unbiased identification of synergistic combinations
from high-throughput experimental data are highly needed
for systematic and reproducible discovery process.
To address this need, we implemented SynergyFinder
(13), a web-application that enables researchers to pre-
process, analyze and visualise pairwise drug combinations
in an interactive manner. SynergyFinder scores drug com-
bination synergy based on user’s selection among the vari-
ous reference models, and the web-tool supports interactive
exploration and comparison of the synergy results. In ad-
dition to quantifying the overall synergies, SynergyFinder
highlights the dose ranges with the strongest synergy or
antagonism for more detailed analyses and interpretation
about the clinical feasibility of the combination treatment.
Since its initial release, SynergyFinder has been used in
a wide range of precision medicine applications, includ-
ing targeted drug combination discovery (14–16), drug re-
sistance analysis (17), finding new vulnerabilities for mu-
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tated tumors (18,19) and comparative evaluation of synergy
scoring models (20). Furthermore, the open-source Syner-
gyFinder implementation has served as a building block
and platform for the development of other drug combina-
tion analysis tools, including DECREASE (21) and Syn-
ToxProfiler (22).
Currently, the search for combinatorial discoveries is wit-
nessing a paradigm shift from the traditional ‘two drugs in
combination’ to the more complex ‘multi-drug cocktails’
(23–29). As a result, higher-order combination therapies
involving three or more drugs have been approved or in-
vestigated for multiple diseases (e.g. cancers, HIV and tu-
berculosis) (1,3,5). For example, a so-called R-CHOP ther-
apy that involves five drugs is an approved curative therapy
for Diffuse Large B-Cell Lymphoma (30). The search for
such higher-order synergistic combinations by industry and
academia has also led to the generation of dose–response
data for a large number of multi-drug combinations (31).
However, most of the tools designed to analyse pairwise
combinations do not naturally extend to scoring higher-
order interaction, as the mathematical implementation of
the referencemodels (e.g. HSA, Loewe and Bliss model) dif-
fers with the addition of each new drug. Furthermore, the
visualization of higher-order interactions becomes increas-
ingly complex, and non-intuitive visualizations can easily
bias the conclusions about the degree of synergy. Addition-
ally, understanding the contribution of each drug in a cock-
tail to the joint response requires a systematic assessment of
all the sub-combinations (32). Therefore, there is a need for
a software tool that cannot only assess synergy/antagonism
of a large number of multi-drug combinations, but also en-
able an interactive exploration of the synergy patterns for
an unbiased analysis of higher-order drug combination ex-
periments.
Here, we present SynergyFinder version 2.0, an upgraded
and improved web-application that enables the analysis of
both pairwise and higher-order drug combination data.
Based on the users’ requests, SynergyFinder 2.0 implements
also novel and improved analysis and visualization options
for multi-drug combination data, including automated out-
lier detection procedure, extended curve-fitting functional-
ity, statistical assessment of replicate measurements, as well
as many other enhancements appearing in the latest imple-
mentation of SynergyFinder.
MATERIALS AND METHODS
Overview of the extended functionality of SynergyFinder 2.0
Details of the original SynergyFinder implementation and
its features for synergy assessment between two drugs have
been described previously (13). Here, we primarily focus
on the enhancements made to support synergy scoring for
higher-order combinations, in addition to other web-tool
improvements. More specifically, SynergyFinder 2.0 imple-
ments (i) efficient synergy estimation for multi-drug combi-
nations, (ii) various curve-fitting algorithms for single drug
dose–responses, (iii) automatic outlier detection in multi-
drug combination screening data, (iv) novel visualization
and export options and (v) statistical treatment of replicate
measurements. A detailed comparison between the features
of SynergyFinder release 1.0 and 2.0 is provided in Table 1.
SynergyFinder 2.0 analysis of multi-drug combinations
Similar to SynergyFinder 1.0, version2.0 supports interac-
tive analysis of two-drug combination data, based on the
user-uploaded dose–response matrices (Figure 1A). As a
result, interactive synergy distribution plots, together with
summary synergy scores, are generated for each pair of
drugs. In addition, SynergyFinder 2.0 supports the anal-
ysis of higher-order drug combinations by implementing
interactive dose–response tensors for each triplet of the
drugs (Figure 1B). Furthermore, barplots of synergy scores
are produced separately for each sub-combination (pairs,
triplets, etc.), depending on the number of drugs in the com-
binations. For more systematic analysis of the contribution
of each drug to the joint higher-order combination effect,
3D synergy landscape plots for each of the two-drug sub-
combinations are visualized enabling their further investi-
gation (Figure 1C).
SynergyFinder 2.0. implements four reference synergy
models (HSA, Bliss, Loewe and ZIP), and their extensions
to calculate synergy scores for higher-order combination
data. These models quantify the degree of synergy either as
the excess over the maximum single drug response (HSA),
multiplicative effect of single drugs as if they acted indepen-
dently (Bliss), expected response corresponding to an addi-
tive effect as if the single drugs were the same compound
(Loewe), and expected response corresponding to the effect
as if the single drugs did not affect the potency of each other
(ZIP). More specifically, the following higher-order formu-
lations were used to quantify the drug combination synergy
(S) for themeasuredmulti-drug combination effect between
N drugs EA,B,...,N:
SHSA = EA,B,...,N − max(EA, EB, . . . , EN).
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Table 1. Comparison of specific features between SynergyFinder release 1.0 and release 2.0
Category Release 1.0 Release 2.0
Synergy assessment Two-drug combinations Multi-drug combinations (two or more)
Outlier detection No Yes
Curve-fitting algorithm Four-parameter logistic regression Four-parameter logistic regression, linear
regression, LOESS fitting
Replicate analysis No Yes
Minimum number of measured drug
doses
Three doses One dose
Visualization options 2D and 3D interactive surface plots,
curve fit plots, heatmaps
2D and 3D interactive surface plots, curve fit
plots, heatmaps, interactive 3D tensor plots, bar
graphs
Reporting Static and dynamic reports Static, dynamic, and short reports. Simultaneous
export of multiple synergy metrics and measured
synergy values.
Here, EA, EB, . . . , EN are the measured responses of the
single drugs, while a, b and n are the doses of the single drugs
required to produce the combination effect EA,B,...,N. For
the ZIP model, xN is the dose of Nth drug fitted with four-
parameter log-logistic (4PL) function, whereas mN is the
dose that produces the half-maximum effect (also known
as relative EC50 or IC50, depending on the readout), and
λN is the shape parameter indicating the slope of the dose–
response curve.
Curve fitting and outlier detection in drug screening data
Accurate fitting of the dose–response curves is the first
necessary step for any synergy assessment, since the fit-
ted dose-response values are used for outlier detection and
calculation of expected effects using the reference models
(e.g. Bliss). The most commonly-used curve-fitting model
for single-drug dose–responses is the four-parameter logis-
tic (4PL) equation (33–35), which is also the default op-
tion in SynergyFinder. However, since some drug dose–
responses may not accurately follow the 4PL model (e.g.
U-shaped curves), SynergyFinder 2.0 allows users also to
apply LOESS fit and linear regression as alternative algo-
rithms for curve fitting. In case of replicate measurements,
the dose–response curves are fitted using all the replicates,
hence improving the robustness against outliers.
For automated detection of outlier measurements both
in the combination and individual agent dose–response
measurements, we utilized our recently-developed machine
learning model, which is built on novel composite non-
negativematrix factorization (cNMF) algorithm (21).More
specifically, SynergyFinder 2.0 uses the cNMF algorithm
to capture the overall combination patterns and to predict
the full dose–response tensors for each combination. Then,
the predicted responses are compared against the observed
ones, and the user is alerted about any measurements that
deviate >20% inhibition from the measured inhibition level
as possible outlier measurements. The synergy calculations
and visualizations can be performed with or without using
the outlier measurements.
SynergyFinder 2.0 input and output options
SynergyFinder 2.0 allows two possible drug screening data
input file formats (Table and Matrix), with the file exten-
sions either as *.xlsx, *.csv or *.txt files. More information
about the input data format is given in the technical doc-
umentation available at https://synergyfinder.fimm.fi, ‘User
guide’ button. Due to the various combination matrix lay-
outs and experimental designs applied in screening projects,
SynergyFinder 2.0 does not impose any restrictions on the
drug combination design. Unlike the previous versions, the
new version accepts both the ‘full combination designs’,
where each drug is measured at multiple doses (36,37), as
well as ‘partial combination designs’, where only a fixed sin-
gle dose is used for any given drug (29,38). However, in the
partial designs, only the Bliss and HSA synergy scores can
be calculated, since Loewe and ZIPmodels require multiple
doses for fitting dose–response curves of each drug in the
combination. In the case of replicate measurements, Syner-
gyFinder 2.0 also reports standard deviations for each syn-
ergy score, which enable statistical analyses of the combina-
tion effects.
For each multi-drug combination, SynergyFinder 2.0
quantifies the selected synergy scores for each combination
of single-drug concentration mixtures, in addition to calcu-
lating the summary synergy level for the combination ef-
fect, i.e. the average of synergy scores over all the measured
(non-outlier) concentrations. SynergyFinder 2.0 generates
three types of summary PDF reports, which show subsets
of the drug combinations, depending on the user’s choices.
For higher-order combinations, each triplet of drugs is vi-
sualized using 3D the dose–response tensor (Figure 1B),
while separate 2D and 3D synergy landscapes between each
pairs of two drugs are generated at different concentrations
of Nth drug (Figure 1C). The summary synergy scores be-
tween all the sub-combinations of drugs (pairs, triplets, etc)
are visualized as summary barplots. Based on the user re-
quests, one can also simultaneously export alternative sum-
mary tables (e.g. tables of multiple synergy scores and raw
synergy results). These tables allow users to process the syn-
ergy results in other analytical or graphical software.
CONCLUSIONS
We have implemented SynergyFinder version 2.0, a web-
based application that enables the users to interactively as-
sess, explore and visualize synergy in multi-drug combina-
tion assays. By allowing users to select various functions
to fit the dose–response curves, cleaned by automated out-
lier detection procedure, SynergyFinder provides a flexible
and robust solutions for an efficient and reproducible syn-
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Figure 1. SynergyFinder 2.0 visual analytic options for (A) pairwise combinations and (B) higher-order combinations. (C) 3D synergy landscapes shown
separately for each two-drug sub-combination.
ergy scoring and visualization of multi-drug combinations
from high-throughput screens. The use of multiple refer-
ence models to estimate synergy will also enable an unbi-
ased evaluation of the pre-clinical significance of combina-
tions toward further development for clinical applications.
The web-tool facilitates both the drug combination discov-
ery and screening programs, as it serves as the single point
solution supporting multiple aspects of high-throughput
combinatorial screening (e.g. outlier detection, curve fit-
ting, and synergy scoring), thereby significantly reducing
the time needed for the data analysis and interpretation.
SynergyFinder 2.0 helps to assess the synergy scores for
any Nth order combinations, with the only restriction that
all the corresponding single-drug responses should be mea-
sured at least with one concentration.We recommend using
multi-dose assays formore accurate synergy landscape anal-
yses, whereas fixed single-dose designs can be used for initial
candidate screening. For two-drug combinations, one can
also use our DECREASE model to predict the full dose–
response matrices based on the more cost-effective fixed-
dose or diagonal designs (21). We encourage users of Syner-
gyFinder to continue leaving comments or suggestions for
further improvements using the feedback form available on
the website, as well as implement or request extended func-
tionality through GitHub repository, with the aim of mak-
ing SynergyFinder even more interactive and user-friendly.
DATA AVAILABILITY
SynergyFinder 2.0 is an open-source software freely avail-
able at https://synergyfinder.fimm.fi without any login re-
quirements. The software comes with example drug com-
bination data, video tutorial and technical user instruc-
tions. The source codes of the web-application implementa-
tion are available at https://github.com/IanevskiAleksandr/
SynergyFinder (under the BSD3-clause license) to allow ex-
tension of the tool for further applications and integration
with other software solutions.
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